The efficacy of omalizumab (blocking the IgE-mediated activation of MC), mepolizumab (anti-IL-5), and dupilumab (anti-IL-4/IL-13) in improving CRSwNP endpoints is an indirect demonstration of the pathogenetic role of these cell subsets [67]. This evidence concerns the gene IL4 and chronic rhinosinusitis with nasal polyps.